



Exelixis Announces February 9 Webcast of Presentation at the 12th Annual BioCEO and Investor Conference

February 4, 2010

SOUTH SAN FRANCISCO, Calif., Feb 04, 2010 (BUSINESS WIRE) -- Exelixis, Inc. (NASDAQ: EXEL) announced today that George A. Scangos, PhD, the company's president and chief executive officer, will present at the 12th Annual BioCEO & Investor Conference at 8:30 a.m. EST / 5:30 a.m. PST on Tuesday, February 9, 2010 in New York. Dr. Scangos will discuss the company's corporate strategy and development pipeline.

The event will be webcast and may be accessed in the Event Calendar page under Investors at <http://www.exelixis.com>.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including Bristol-Myers Squibb, sanofi-aventis, GlaxoSmithKline, Genentech (a wholly owned member of the Roche Group), Boehringer Ingelheim, Pfizer Inc., and Daiichi-Sankyo. For more information, please visit the company's web site at <http://www.exelixis.com>.

Exelixis and the Exelixis logo are registered U.S. trademarks.

SOURCE: Exelixis, Inc.

Exelixis, Inc.

Investor Contacts:

Charles Butler, 650-837-7277

Vice President, Investor Relations

and Corporate Communications

cbutler@exelixis.com

DeDe Sheel, 650-837-8231

Associate Director, Investor Relations

dsheel@exelixis.com